Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Lipid Screening in Children with NAFLD

J Pediatr; ePub 2018 Apr 13; Harlow, et al

More than 50% of children with nonalcoholic fatty liver disease (NAFLD) met intervention thresholds for dyslipidemia, warranting lipid screening in this population group. This according to a multicenter, longitudinal cohort study that included 585 children (mean age 12.8 years) with NAFLD. Fasting lipid profiles were obtained at diagnosis. After 1 year, lipid profiles were repeated and interpreted according to National Heart, Ling, and Blood Institute Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction. Main outcomes were meeting criteria for clinically actionable dyslipidemia at baseline, and either achieving lipid goal at follow-up or meeting criteria for ongoing intervention. Researchers found:

  • The prevalence of children warranting intervention for low-density lipoprotein cholesterol (LDL-C) at baseline was 14%.
  • After 1 year of recommended dietary changes, 51% achieved goal LDL-C, 27% qualified for enhanced dietary and lifestyle modifications, and 22% met criteria for pharmacologic intervention.
  • Elevated triglycerides were more prevalent, with 51% meeting criteria for intervention.

Citation:

Harlow KE, Africa JA, Wells A, et al. Clinically actionable hypercholesterolemia and hypertriglyceridemia in children with nonalcoholic fatty liver disease. [Published online ahead of print April 13, 2018]. J Pediatr. doi:10.1016/j.jpeds.2018.02.038.

This Week's Must Reads

Anticoagulation in Patients with AF and HF, Clin Cardiol; ePub 2018 Dec 23; Contreras, et al

Serum Uric Acid, Silent MI & Mortality, Am J Cardiol; ePub 2018 Dec 19; Ahmad, et al

Catheter Ablation for AF in Adults with CHD, Heart Rhythm; ePub 2018 Dec 26; Liang, et al

Cognitive Impairment in Adults with Incident HF, J Card Fail; ePub 2018 Dec 22; Sterling, et al

LDL-C Level Reduction Consistent with Evolocumab , JAMA Cardiol; ePub 2018 Dec 12; Qamar, et al

Must Reads in Hypercholesterolemia

LDL-C Level Reduction Consistent with Evolocumab , JAMA Cardiol; ePub 2018 Dec 12; Qamar, et al

Hypertriglyceridemia in Statin-Treated Adults, J Clin Lipidol; ePub 2018 Dec 1; Fan, et al

AHA Statement: Statin Safety & Adverse Events, Arterioscler Thromb Vasc Biol; ePub 2018 Dec 10; Newman, et al

LDL-C Reduction & Arterial Wall Inflammation, Eur Heart J; ePub 2018 Dec 18; Stiekema, et al

Holiday Season and Risk of Hypercholesterolemia, Atherosclerosis; ePub 2018 Dec 19; Vedel-Krogh, et al